Gonsette R E
National Centre for Multiple Sclerosis, B 1820 Melsbroek, Belgium.
J Neurol Sci. 2008 Nov 15;274(1-2):48-53. doi: 10.1016/j.jns.2008.06.029. Epub 2008 Aug 5.
In multiple sclerosis (MS) disability results from neuronal and axonal loss, the hallmark of neurodegenerative diseases (ND). Neurodegeneration is initiated by microglia activation and mediated by oxidative stress and excitotoxicity. The same sequence of events has been consistently observed in MS. However, microglia activation correlates with a marked cell infiltration in MS but not in ND. In both pathological states, peroxynitrite is the common initiating factor of oxidative stress and excitotoxicity and is thus a potential interesting therapeutic target. Oxidative stress leads to multiple lipid and protein damages via peroxidation and nitration processes. The pathomechanisms of excitotoxicity are complex involving glutamate overload, ionic channel dysfunction, calcium overload, mitochondriopathy, proteolytic enzyme production and activation of apoptotic pathways. The inflammatory component in MS is important for the design of therapeutic strategies. Inflammation not only causes axonal and neuronal loss but it also initiates the degenerative cascade in the early stage of MS. Potent anti-inflammatory agents are now available and it is not unreasonable to think that an early blockade of inflammatory processes might also block associated degenerative mechanisms and delay disability progression. The development of neuroprotective drugs is more problematic. Indeed, given the multiple and parallel mechanisms involved in neurodegeneration, modulation of a single specific pathway will likely yield a partial benefit if any.
在多发性硬化症(MS)中,残疾是由神经元和轴突丧失导致的,这是神经退行性疾病(ND)的标志。神经退行性变由小胶质细胞激活引发,并由氧化应激和兴奋性毒性介导。在MS中一直观察到相同的事件序列。然而,小胶质细胞激活在MS中与明显的细胞浸润相关,而在ND中则不然。在这两种病理状态下,过氧亚硝酸盐都是氧化应激和兴奋性毒性的常见起始因素,因此是一个潜在的有趣治疗靶点。氧化应激通过过氧化和硝化过程导致多种脂质和蛋白质损伤。兴奋性毒性的发病机制很复杂,涉及谷氨酸过载、离子通道功能障碍、钙过载、线粒体病变、蛋白水解酶产生以及凋亡途径的激活。MS中的炎症成分对于治疗策略的设计很重要。炎症不仅会导致轴突和神经元丧失,还会在MS的早期引发退行性级联反应。现在有强效的抗炎药物,认为早期阻断炎症过程可能也会阻断相关的退行性机制并延缓残疾进展并非不合理。神经保护药物的开发则更具问题。实际上,鉴于神经退行性变涉及多种并行机制,调节单一特定途径可能只会带来部分益处(如果有的话)。